Novartis, the world's second largest pharmaceutical company, has announced that its antimalarial medicine Coartem 80/480mg received World Health Organisation (WHO) prequalification, making it the first and only high strength (80/480mg) artemisinin-based combination therapy (ACT) antimalarial treatment available for public sector procurement. This new dosage strength has the potential to improve malaria management.
Sandoz, a Novartis company, has launched Glatopa in US markets. Glatopa is the first generic version of Teva's Copaxone (glatiramer acetate injection) 20 mg/ml one-time-daily multiple sclerosis therapy. It is used in treatment of Multiple Sclerosis (MS).
The US Food and Drug Administration (FDA) has approved Novartis' Promacta (eltrombopag) for the treatment of children six years and older with chronic immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy. Promacta was approved by the FDA in 2008 for use in adult patients with the same condition.
CLICK HERE TO SUBSCRIBE,
PHARMATUTOR's DAILY EMAILS
Do Not Forget to Verify
(Click on Subscription link in your inbox)
--------
A global healthcare leader, Novartis has one of the most exciting product pipelines in the industry today. A pipeline of innovative medicines brought to life by diverse, talented and performance driven people. All of which makes them one of the most rewarding employers in their field.
